Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

ACCELERATING STROKE TREATMENT INNOVATION THROUGH AN AI-ENABLED IN-SILICO NEW APPROACH METHODOLOGY (NAM)

Ziel

Stroke remains the primary cause of adult disability and the second leading cause of death in the European Union, imposing a global economic burden of over €890 billion. The current design and development of thrombectomy devices is primarily driven by trial-and-error methodologies utilizing models with suboptimal translational capability to the actual clinical environment. Traditional preclinical validation relies on animal models and oversimplified bench tests that fail to predict human outcomes. 90% of neurovascular treatments that show promise in preclinical stages fail to achieve their primary endpoints in human clinical trials. Moreover, developing medical devices is an inefficient process, costing up to €100 million per device and development cycles lasting up to eight years.
inSteps B.V. addresses this crisis through the world’s first high-fidelity In-Silico Thrombectomy Digital Twin Platform. By merging state-of-the-art Finite Element Method (FEM) simulations with Generative AI, the platform creates a revolutionary virtual trial environment powered by a unique database of 4,500 real-world patients. This allows for the synthesis of diverse virtual cohorts to simulate the intricate mechanical interactions between medical devices, vascular anatomy, and human-derived clots with unprecedented precision. By providing a fail-fast mechanism, this data-driven approach allows developers to rapidly iterate and discard suboptimal prototypes before significant capital is committed. This ensures only the most promising technologies advance and de-risks clinical trials, increasing the probability of success and a streamlined path to regulatory approval.
This paradigm shift transforms the R&D landscape, slashing design iteration cycles from six weeks to just five days and reducing development expenditures from €5 million to less than €500,000 per project. inSteps directly supports the EU Biotech Act and the EMA’s 3Rs strategy to replace, reduce, and refine animal testing.

Wissenschaftliches Gebiet (EuroSciVoc)

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-EIC - HORIZON EIC Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) HORIZON-EIC-2026-AIC

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Koordinator

INSTEPS BV
Netto-EU-Beitrag
€ 300 000,00
Adresse
ROETERSSTRAAT 35
1018WB Amsterdam
Niederlande
KMU
Ja
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
Keine Daten